



# Development and Benchmarking of a Monte Carlo Dose Engine for Proton Radiation Therapy

Peter Lysakovski<sup>1,2</sup>, Alfredo Ferrari<sup>1</sup>, Thomas Tessonnier<sup>1</sup>, Judith Besuglow<sup>1,2,3,4,5</sup>, Benedikt Kopp<sup>1</sup>, Stewart Mein<sup>1,3,4,5</sup>, Thomas Haberer<sup>1</sup>, Jürgen Debus<sup>1,5,6</sup> and Andrea Mairani<sup>1,7,3,8\*</sup>

<sup>1</sup>Department of Radiation Oncology, Heidelberg Ion Beam Therapy Center (HIT), Heidelberg University Hospital, Heidelberg, Germany, <sup>2</sup>Faculty of Physics and Astronomy, Heidelberg University, Heidelberg, Germany, <sup>3</sup>Clinical Cooperation Unit Translational Radiation Oncology, German Cancer Consortium (DKTK) Core-Center Heidelberg, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ), Heidelberg, Germany, <sup>4</sup>Division of Molecular and Translational Radiation Oncology, Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD), Heidelberg, Germany, <sup>5</sup>Heidelberg Faculty of Medicine (MFHD) and German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD), Heidelberg, Germany, <sup>5</sup>Heidelberg Faculty of Medicine (MFHD) and German Cancer Research Center (DKFZ), Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), Heidelberg University Hospital (UKHD), Heidelberg, Germany, <sup>6</sup>Clinical Cooperation Unit Radiation Oncology, German Cancer Consortium (DKTK) Core-Center Heidelberg, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ), Heidelberg, Germany, <sup>6</sup>Clinical Cooperation Unit Radiation Oncology, German Cancer Consortium (DKTK) Core-Center Heidelberg, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ), Heidelberg, Germany, <sup>7</sup>Medical Physics, National Centre of Oncological Hadrontherapy (CNAO), Pavia, Italy, <sup>8</sup>Medical Faculty, Heidelberg University, Heidelberg, Germany

#### **OPEN ACCESS**

#### Edited by:

Miguel Antonio Cortés-Giraldo, Sevilla University, Spain

#### Reviewed by:

Adam Aitkenhead, The Christie National Health Service Foundation Trust, United Kingdom Matteo Duranti, Istituto Nazionale di Fisica Nucleare di Perugia, Italy

> \*Correspondence: Andrea Mairani Andrea.Mairani@med.uniheidelberg.de

#### Specialty section:

This article was submitted to Radiation Detectors and Imaging, a section of the journal Frontiers in Physics

Received: 14 July 2021 Accepted: 15 October 2021 Published: 03 November 2021

#### Citation:

Lysakovski P, Ferrari A, Tessonnier T, Besuglow J, Kopp B, Mein S, Haberer T, Debus J and Mairani A (2021) Development and Benchmarking of a Monte Carlo Dose Engine for Proton Radiation Therapy. Front. Phys. 9:741453. doi: 10.3389/fphy.2021.741453 Dose calculation algorithms based on Monte Carlo (MC) simulations play a crucial role in radiotherapy. Here, the development and benchmarking of a novel MC dose engine, MonteRay, is presented for proton therapy aiming to support clinical activity at the Heidelberg Ion Beam Therapy center (HIT) and the development of MRI (magnetic resonance imaging)-guided particle therapy. Comparisons against dosimetric data and gold standard MC FLUKA calculations at different levels of complexity, ranging from single pencil beams in water to patient plans, showed high levels of agreement, validating the physical approach implemented in the dose engine. Additionally, MonteRay has been found to match satisfactorily to FLUKA dose predictions in magnetic fields both in homogeneous and heterogeneous scenarios advocating its use for future MRI-guided proton therapy applications. Benchmarked on 150 MeV protons transported on a  $2 \times 2 \times 2 \text{ mm}^3$  grid, MonteRay achieved a high computational throughput and was able to simulate the histories of more than 30,000 primary protons per second on a single CPU core.

Keywords: Monte Carlo (MC), dose calculation, radiotherapy, magnetic field, proton

# INTRODUCTION

Image guided radiotherapy is at the forefront of innovative treatment delivery techniques. It has the potential to improve treatment efficacy via on-board imaging procedures such as adaptive planning and/or live monitoring, for instance via magnetic resonance (MR)-guided radiation therapy (MRgRT) [1, 2]. Over the last decade, clinical prototypes have combined low-field-strength MR and radioactive cobalt-60 sources for photon treatment, followed by linear accelerators and higher field-strength MR fields for improved image resolution [3–5].

1

Particle therapy (PT), a cancer treatment modality achieving superior dose conformity to solid tumours compared to conventional photon techniques [6, 7], would greatly benefit from on-board MR-guided treatment delivery [8]. For instance, at the Heidelberg Ion Beam Therapy Center (HIT) over 5,000 patients have been treated with proton and carbon ions since 2009 [9]. While <sup>16</sup>O ions have so far only been used for research purposes, HIT has treated the first patient with raster scanning <sup>4</sup>He ion beams in July 2021.

For all clinically administered ion beams, on-board MRguided treatment delivery is currently not feasible. However, system developments for treatment planning and delivery of MR-guided particle therapy are underway at HIT. Here, we begin with considerations in dose calculation for MR-guided particle therapy. During MRgRT using photons, for example, the MR field (due to Lorentz forces) can impact the dose deposition of ionized electrons/delta-rays, with severity depending on patient anatomy and MR field strength [10, 11]. Hence, dose calculation corrections are introduced in clinical practice for improving accuracy [12]. Similarly, trajectories of fast charged particles like protons are altered by the MR field [13–15] and consequently, proper consideration must be given for accurate dose calculation.

With the aim of providing dose computations at various levels of accuracy and speed for current and future treatment in particle therapy with light and heavy ions, various systems have been introduced at HIT to support clinical deployment of PT. Initially, as a gold standard, a MC environment based on the MC code FLUKA [16, 17] has been developed and extensively benchmarked [18] for allowing database generation for clinical analytical treatment planning system (TPS) and patient recalculations. This framework required long computation times (hours to days depending on the number of CPUs available) which limited its usage in the analysis of large patient cohorts and for any adaptive/on-line planning.

In order to overcome these limitations, FRoG (Fast dose\* Recalculation on GPU) has been introduced, an advanced analytical code capable of calculating dose, LET<sub>d</sub> (dose-weighted Linear Energy Transfer) and biological dose for the four particle beams available at HIT [19-21] and which is in use at other PT facilities in Europe (Centro Nazionale di Adroterapia Oncologica [21], Danish Centre for Particle Therapy [22]. High levels of agreement within 1-2% [19, 21, 23] were found comparing FLUKA and FRoG recalculated dose-volume-histograms (DVH) of proton and other light ion patient plans even for complex cases such as lung irradiation [23]. However, analytical codes are usually designed for a specific task, making the introduction of new features such as MR-guidance [14, 24], positron emission tomography [25, 26] and prompt gammas [27] require large development effort and substantial changes in the physics engine. Fast MC engines have been introduced for proton beams [28-33] and helped streamline the development while reaching various levels of agreement when compared against gold standard MC codes such as FLUKA and TOPAS/Geant [34].

Several recent works have investigated the impact of MRguidance on particle beam physics and modelling distortion due to the Lorentz force [13, 35–38]. Despite these characterizations however, no fast MC engine has been presented in literature which is able to perform clinically relevant particle therapy calculations in magnetic fields. In this work, a CPU-based fast MC dose engine for proton beams (MonteRay) was developed and benchmarked for supporting ongoing clinical activity and introducing novel treatment modalities, particularly within the MRI-guided particle therapy program at HIT.

# MATERIALS AND METHODS

#### **Programming Languages and Libraries**

With performance and extensibility to GPUs in mind, the MonteRay MC engine was written in C++. Several external libraries were used either during development or execution of the MC code. The frameworks GoogleTest [39] and Benchmark [40] are used for testing and microbenchmarking the source code. The Boost library [41] is used for filesystem operations and parsing of configuration files. RapidXml [42] is used for reading of irradiation plans in XML format. ITK [43] and DCMTK [44] are used for reading CT images. FLUKA simulations were performed using FLUKA version 2020 0.6.

# **Geometry and Materials**

Voxelized water phantom and patient geometries are implemented from computed tomography (CT) scans using the approach described in [45, 46], i.e. the Hounsfield Unit (HU) of each voxel is converted to a water equivalent path length, density and elemental composition. In total, 36 different materials, covering an HU range between -1000 HU and 3070 HU are used. HU values larger than 3070 are assumed to be metallic implants made from titanium. Each material is modeled as a combination of up to ten elements. Additionally, five extra materials (water, RW3, PMMA, air and carbon fiber) can be defined by the user for dosimetric studies. For the calculation of nuclear interactions, only the most abundant isotope of each element is considered: <sup>1</sup>H, <sup>12</sup>C, <sup>14</sup>N, <sup>16</sup>O, <sup>23</sup>Na, <sup>24</sup>Mg, <sup>31</sup>P, <sup>32</sup>S, <sup>35</sup>Cl, <sup>40</sup>Ar, <sup>39</sup>K, <sup>40</sup>Ca and <sup>48</sup>Ti. However, just H, C, O and Ca already constitute more than 90% of a human's weight [47]. Including more materials in MonteRay is trivial if they consist only of the ten base elements already defined. Adding additional elements requires the generation of additional inelastic nuclear interaction databases (Inelastic Nuclear Interactions).

# Handling the HIT-specific Beamline

The HIT beamline consists of various layers of different materials, including tungsten [48], with which the particle beam interacts before reaching the patient, resulting in a unique phase-space of particles. To avoid modelling and simulating the whole beamline in MonteRay, the approach described in [49] was used, i.e., sampling from a phase-space for each of the 255 quasi-monoenergetic proton beams available at the HIT facility. Each file contains the location, direction and energy of 10 million particles sampled on a plane perpendicular to the beam's direction before the patient's entrance. The phase space was generated using FLUKA and besides primary protons, secondary protons generated due to the primary particle's

interactions with the beamline are also considered. For now, however, all other secondary particles (deuterons, tritons, <sup>3</sup>He, <sup>4</sup>He and neutrons) are neglected. During simulation, our MC code randomly samples individual particles from these phase space files.

# Transport

For the simulation of proton beams, MonteRay performs the transport of protons, deuterons, tritons, 3-Helium and 4-Helium. Of these particles, only protons undergo elastic and *Inelastic Nuclear Interactions* as described in *Nuclear Interactions*. All transported particles experience energy loss and scattering through electromagnetic interactions as described in *Electromagnetic Interactions*.

Energy is deposited either on a Cartesian or a cylindrical grid. Energy depositions from heavy nuclear recoils are recorded locally while energy lost through electromagnetic interactions are deposited along a track via the method described in [50]: given the particle's location at the beginning of the transport step  $\vec{x_i}$  and its position at the end of the transport step  $\vec{x_f}$ , the point of energy deposition is chosen randomly *via* 

$$\overrightarrow{x_{dep}} = \overrightarrow{x_i} \cdot (1 - U) + \overrightarrow{x_f} \cdot U, \qquad (1)$$

where U is a random number uniformly distributed on the interval [0, 1). This is an efficient method of avoiding aliasing effects due to floating-point inaccuracies at grid boundaries and mismatches between the CT and the scoring grid. To avoid discontinuities in the deposited dose, the particles are transported on a grid with spacing equal to or less than the requested scoring grids spacing. If a CT is loaded, this will be the CT grid. All simulations shown here, unless otherwise noted, were performed on a  $1 \times 1 \times 1 \text{ mm}^3$  Cartesian grid. At the beginning of each step, the distance to the next voxel's boundary  $dx_{vox}$  is calculated and the distance to the next nuclear interaction  $dx_{nuc}$  is sampled based on the total nuclear cross section introduced in *Nuclear Interactions*. The smaller of these two values is chosen as the current iteration's step length dx, i.e.

$$dx = \min(dx_{vox}, dx_{nuc}).$$
(2)

The energy loss over the distance dx is calculated and the scattering angle is sampled after the approaches described in *Electromagnetic Interactions*. In the presence of a magnetic field  $\vec{B}$ , an additional deflection  $\Delta u_m$  due to the Lorentz force is calculated after [51] using

$$\overrightarrow{\Delta u_m} = \frac{\left(\vec{u} \times \vec{B}\right) \cdot z \cdot c \cdot dx}{m \cdot y \cdot \beta},$$
(3)

where m is the particle's rest mass, z is the particle's charge in units of the elementary charge,  $\beta$  is its velocity relative to the speed of light c,  $\vec{u}$  is its normalized direction and  $\gamma$  is the Lorentz factor.

After updating the particle's position, energy and direction, if a nuclear interaction occurred, the type of nuclear interaction is determined, and the nuclear interaction performed as will be described in *Nuclear Interactions*. The transport step is repeated

until the particle's energy falls below a threshold of 1 MeV. The remaining energy is deposited in a single step. During transport, only protons undergo nuclear interactions. For all other particles, only electromagnetic energy losses are considered.

Angular deflections due to nuclear or electromagnetic interactions, expressed through a polar angle  $\theta$  and an azimuthal angle  $\phi$ , are applied to the particle's initial direction  $\vec{u}$  to obtain the particle's final direction  $\vec{u'}$  via:

$$\vec{u'} = \vec{v} \cdot \sin(\theta) \cdot \cos(\phi) + \vec{w} \cdot \sin(\theta) \cdot \sin(\phi) + \vec{u} \cdot \cos(\theta) \quad (4)$$

where the vectors  $\vec{v}$  and  $\vec{w}$  are chosen such that together with  $\vec{u}$ , they form an orthonormal basis. Since all physical interactions considered in the simulation are independent of  $\phi$ , any orthonormal basis can be used for this purpose. To find  $\vec{v}$ , a run-time efficient algorithm described in [52] is used. The last constituent of the orthonormal basis is then computed using the cross product  $\vec{w} = \vec{u} \times \vec{v}$ .

### **Electromagnetic Interactions**

Interactions with electrons cause charged particles to continuously lose energy while travelling through matter. The mean energy loss per unit distance due to this process is called the stopping power S, which is a function of energy and dependent on the projectile's mass and charge [53, 54]. FLUKA was used to tabulate the energy loss of the transported particles in water from 0.1 MeV/ u to 1,000 MeV/ u with 2000 linearly spaced intervals. To obtain the stopping power in materials other than water, the stopping power table for water was multiplied by a factor dependent on the materials HU value [45]. Since the step size dx is fixed at the beginning of each transport step, the mean energy loss dE that the particle experiences during the step must be calculated. This problem is equivalent to solving the following equation:

$$E(dx) = E_0 - \int_0^{dx} S(E(y)) dy$$
(5)

where E(x) is the particles energy after having travelled a distance x and  $E_0$  is the particle's energy at the beginning of the step. While this equation is in principle solvable under the assumption that S is linear along the step, a numerical approximation was used instead. This approximation is based on the following recurrence relation:

$$\overline{\mathbf{dE}_0} = \mathbf{dx} \cdot \mathbf{S}(\mathbf{E}_0) \tag{6}$$

$$\overline{\mathbf{dE}_{\mathbf{n}}} = \mathbf{dx} \cdot \mathbf{S} \left( \mathbf{E}_{0} - \frac{\overline{\mathbf{dE}_{\mathbf{n}-1}}}{2} \right).$$
(7)

This recurrence relation is evaluated up to a depth of n = 3 to arrive at an accurate estimate of  $\overline{dE}$ .

Scattering is a statistical process, so the stopping power only describes the mean energy loss per unit distance traveled. Theoretical treatments of this process have for example been done in [55, 56]. The distributions derived therein are complex and their sampling costly. But in the limit were **dx** is

large, the energy loss is approximately distributed normally around  $\overline{dE}$ . If dx is small on the other hand, the Gaussian approximation is inadequate and the distribution is skewed towards high energy losses [54]. Whether a Gaussian approximation is appropriate can be judged through the parameter  $\kappa$  given by

$$\kappa = \frac{\xi}{T_{max}},\tag{8}$$

where  $\boldsymbol{\xi}$  is given by

$$\boldsymbol{\xi} = 2\boldsymbol{\pi} \cdot \boldsymbol{N}_a \boldsymbol{m}_e \boldsymbol{r}_e \boldsymbol{\rho} \cdot \boldsymbol{dx} \cdot \frac{\boldsymbol{q}^2}{\boldsymbol{e}^2} \frac{\boldsymbol{Z}}{\boldsymbol{A}} \cdot \frac{1}{\boldsymbol{\beta}^2}$$
(9)

and  $T_{max}$  is given by

$$\mathbf{T}_{\max} = \frac{2\mathbf{m}_{\mathbf{e}}\boldsymbol{\beta}^{2}\boldsymbol{\gamma}^{2}}{1 + 2\boldsymbol{\gamma}\frac{\mathbf{m}_{\mathbf{e}}}{\mathbf{m}} + \frac{\mathbf{m}_{\mathbf{e}}^{2}}{\mathbf{m}^{2}}},$$
(10)

where  $N_a$  is Avogadro's number,  $m_e$  is the electron's mass,  $r_e$  is the classical electrons radius, q is the particles charge in Coulomb, Z is the target's atomic charge and A is the target's atomic number. Following [57], the energy loss distribution is approximated through a normal distribution if  $\kappa \ge 10$  and a log-normal distribution if  $\kappa < 10$ . The normal distribution has mean  $\overline{dE}$  and standard deviation  $\sigma$  as given for example in [53]:

$$\boldsymbol{\sigma} = \sqrt{\boldsymbol{\xi} \cdot \boldsymbol{T}_{max} \left( 1 - \boldsymbol{0.5} \boldsymbol{\beta}^2 \right)}. \tag{11}$$

The log-normal distribution's parameters are determined through a fit, matching the first four moments of the Vavilov distribution [57]. For very small  $\kappa < 0.3$  [57], propose the use of a different distribution, but with step sizes of 1 mm it was found that adequate agreement can be achieved by sampling from a log-normal distribution even when  $\kappa < 0.3$ . During the simulations, care had to be taken here since occasionally, especially for very low-density materials like air, the energy loss sampled according to the log-normal approximation could become negative. In this case the approximation  $dE = \overline{dE}$  was used.

Besides inelastic collisions with atomic electrons, charged particles also undergo elastic collisions with atomic nuclei. These interactions do not contribute to the particle's energy loss but deflect the particle. This too, is a statistical process. Commonly, MC simulations base their scattering model on Moliere's theoretical treatment [58]. The formula derived by Moliere is a series of functions

$$f(\vartheta) = \sum_{n} \frac{\vartheta f_{n}(\vartheta)}{B^{n}},$$
(12)

where the reduced angle  $\vartheta$  is related to the polar scattering angle  $\theta$  used in Eq. 1 *via* 

$$\vartheta = \frac{\theta}{\chi_c \sqrt{B}} \tag{13}$$

and where  $\chi_c$  and **B** are constants dependent on the target material, the incoming particle's energy and charge. These

constants are defined in [58] together with an integral representation of the functions  $f_n$ . To clear up possible confusions, we note that in literature, frequently not the scattering angle  $\vartheta$  is considered but instead the projected angle  $\varphi$  is used. This angle arises when one considers the projection of  $\vartheta$  onto an axis perpendicular to the beam's direction. For a rigorous definition of  $\vartheta$  and  $\varphi$ , we refer to [58, 59] and here we will only work with the angle  $\vartheta$ .

Sampling from higher order terms of the Moliere distribution is computationally expensive, but approximations can be made. Perhaps the simplest is dropping higher order terms, i.e. terms where  $n \ge 2$ . Since **B** is a measure for the average number of single scattering events occurring along a step, when the step size dx is large the weight of the higher order terms decreases and the distribution can be approximated through a Rayleigh distribution in  $\vartheta$ 

$$\mathbf{f}(\boldsymbol{\vartheta}) \approx \boldsymbol{\vartheta} \exp\left(-\boldsymbol{\vartheta}^2\right) \tag{14}$$

or a Gaussian distribution in  $\varphi$ 

$$\mathbf{f}(\mathbf{\phi}) \approx \exp\left(-\mathbf{\phi}^2\right). \tag{15}$$

Single Gaussian approximations of the scattering angle have for example been introduced by Rossi [60] or Highland [61]. For the width  $\sigma$  of this Gaussian [60], provide the following empirical formula:

$$\sigma = \frac{E_s z}{\beta p} \sqrt{\frac{\rho dx}{\chi_0}},\tag{16}$$

where z is the particle's charge in units of the elementary charge,  $\rho$  is the target's density,  $\chi_0$  is the target's radiation length and p is the particle's momentum in MeV/c. Originally, the value of  $E_s$  was given as 21 MeV but with the mixed Rayleigh-Rutherford approach that will be presented here, a value of 11.6 MeV was found to be better and was used throughout all simulations presented in **Results**.

For small dx, the single Gaussian approximation does not adequately reproduce the large angle tails of Moliere's distribution. As a result, authors have proposed different modifications to the pure Gaussian probability distribution such as double or triple Gaussian parametrizations [62, 63] or parametrizations that use a Rutherford distribution to model the tail [31, 53, 64–66]. Generally, even when using fits of Gaussian mixture models, the large-angle tails of the Moliere distribution are not reproduced adequately. In this work, a parametrization similar to [64] was used, combining a Rutherford-like tail with a Rayleigh distribution at the center

$$P(\theta) = \begin{cases} \frac{\theta}{N\sigma^2} exp\left(-\frac{\theta}{2\sigma^2}\right), & \theta \le \mathbf{k} \\ \frac{\alpha}{N\theta^3}, & \theta > \mathbf{k}. \end{cases}$$
(17)

For the simulations, the value  $k = 3.5\sigma$  was used, the constant  $\alpha$  was determined such that  $P(\theta)$  is continuous at the boundary  $\theta = \mathbf{k}$  and N was determined such that the probability density function is normalized, i.e.

$$\boldsymbol{\alpha} = \frac{\boldsymbol{k}^4}{\sigma^2} \exp\left(-\frac{\boldsymbol{k}^2}{2\sigma^2}\right) \text{ and }$$
(18)

$$N = N_G + N_R. \tag{19}$$

Here,  $N_G$  and  $N_R$  are the integral of the Rayleigh and the Rutherford-like part respectively, given by

$$N_G = 1 - exp\left(-\frac{k^2}{2\sigma^2}\right)$$
 and (20)

$$\mathbf{N}_{\mathbf{R}} = \frac{\mathbf{k}^2}{2\sigma^2} \exp\left(-\frac{\mathbf{k}^2}{2\sigma^2}\right). \tag{21}$$

Sampling of an angle  $\theta$  is then done via inverse transform sampling using only a single uniformly distributed random number U after

$$\boldsymbol{\theta} = \begin{cases} \boldsymbol{\sigma} \sqrt{-2\log\left(1 - U \cdot N\right)}, & U \leq N_G \\ \frac{1}{\sqrt{\frac{1}{k^2} - \frac{2}{\alpha}\left(U \cdot N - N_G\right)}}, & U > N_G \cdot \end{cases}$$
(22)

# Nuclear Interactions

#### **Elastic Nuclear Interactions**

The kinematics involved in elastic nuclear interactions are implemented fully relativistically. The total elastic cross section  $\sigma_{el}$  is calculated starting from the work of [67] and was tabulated in 500 evenly spaced bins ranging from 0.1 to 500.1 MeV for all 10 nuclei listed in *Geometry and Materials*. The scattering angle in the center of mass frame is sampled according to a parametrization proposed in [68]. First, the momentum transfer *t* is sampled after

$$P(t) = A^{1.63} \exp(14.5A^{0.66}t) + 1.4A^{0.33} \exp(10t), \qquad (23)$$

where, *A* is the target nucleus atomic number. Then, the center of mass scattering angle is calculated via

$$\cos\left(\boldsymbol{\theta}_{\mathrm{CM}}\right) = 1 - \frac{\mathbf{t}}{2\mathbf{p}_{\mathrm{CM}}}.$$
(24)

With  $p_{CM}$  being the center of mass momentum. From  $\theta_{CM}$ , the laboratory frame polar scattering angles are computed and, together with a uniformly distributed azimuthal angle, applied to the resulting scattered particles.

#### Inelastic Nuclear Interactions

In particle therapy, inelastic nuclear scattering events generate the mixed radiation field, i.e. photons, protons, neutrons, deuterons, tritons, <sup>3</sup>He, <sup>4</sup>He and heavier fragments (nuclear recoils). In MonteRay, similarly to other works in literature [31, 32], photons and neutrons are assumed to be dosimetrically irrelevant and they are neither transported nor produced. The total inelastic cross section  $\sigma_{ine}$  for protons was calculated starting from the work of [69, 70]. To model the production of secondary particles, a database of nuclear event probabilities was generated based on nuclear models used internally by FLUKA. The database covers a primary proton energy  $T_{in}$  ranging from 10 to 300 MeV,

in steps of 10 MeV. Tables were generated for each of the 10 elements defined in and for each of the five possible product particles considered: protons, tritons, deuterons, 3-Helium and 4-Helium. Each table (of the  $30 \cdot 10 \cdot 5 = 1500$  tables) is divided into 100 bins in the kinetic energy  $T_{sec}$  and 100 bins in the solid angle  $\Omega_{sec}$  of the secondaries. The 100 energy bins divide the range **0** to  $T_{in}$  into evenly spaced intervals and the 100 angular bins evenly divide the interval 0 to 4  $\pi$ . If an inelastic nuclear event occurs during simulation, all possible products for the current target nucleus are created but assigned weights corresponding to their relative multiplicity (Figure 1A). Secondary particle energy (Figure 1B) and direction are chosen via a binary search on a cumulative probability distribution, generated at the beginning of the simulation by summing up the tables values. Additionally, the mean kinetic recoil energy is stored for each table and deposited on the spot following a nuclear event.

# Benchmarking of the Developed Dose Engine

To benchmark MonteRay, its predictions were compared against experimental data acquired at HIT over the last years, published in [71, 72]. For scenarios where experimental data was not available, e.g. in presence of magnetic fields and for patient calculations, FLUKA predictions were used as a reference.

#### **Comparison Metrics**

To judge MonteRay's agreement with measurements or against other TPS, several common radiotherapy metrics were used. The relative error

$$\varepsilon_{\rm rel} = 200 \, \frac{d_1 - d_2}{(d_1 + d_2)} \, [\%]$$
 (25)

was used to quantify the relative disagreement between two dose profiles,  $d_1$  and  $d_2$ . Measured and calculated beam ranges were compared in terms of their  $R_{80}$  value which is defined as the depth distal to the Bragg peak (BP) where the dose falls to 80% of the BP value. The difference in range for two dose distributions was quantified through  $\Delta \mathbf{R}_{80} = |\mathbf{R}_{80}^1 - \mathbf{R}_{80}^2|$ . Agreement between lateral profiles was judged using the full width at half maximum (FWHM) value and the full width at 10% of the maximum (FW10%M) value. For the comparison of 3D dose distributions, the 3D local gamma pass rate was calculated. For this the python package pymedphys version 0.37.1 was used. For the calculation, similar to previous proton MC engines [28, 31, 73, 74], the dose percentage threshold was set to 2%, the distance threshold to 2 mm and the dose cutoff to 5% of the maximum dose. During the calculation of the gamma pass rate, dose outside the patient was not considered as it is clinically irrelevant. Another metric used to evaluate patient plans is the  $D_x$  value. For a given region of interest (ROI), it is defined as the minimum dose that x percent of the ROIs volume is exposed to.

To judge the deflection of a single beam in a magnetic field, we introduce the center of mass (COM) of the beam. Given a lateral profile scored in N bins at locations  $x_i$  with corresponding scored doses  $d(x_i)$ , we define it as



FIGURE 1 | (A) Average number of particles produced per p + <sup>16</sup>O collision as a function of the energy of the incoming proton. (B) For 200 MeV p + <sup>16</sup>O collisions, the angularly integrated probability (in %) of a secondary particle being produced in a certain energy bin (bin size: 10 MeV) is shown. Abbreviations stand for Protons (P), Deuterons (D), Tritons (T), Helium-3 (<sup>3</sup>He) and Helium-4 (<sup>4</sup>He).

$$COM = \frac{1}{N} \sum x_i \cdot d(x_i).$$
 (26)

#### **Dosimetric Data**

Various experimental data that was previously recorded at HIT was used to evaluate MonteRay's performance in terms of dosimetric accuracy. This data, included pencil-beam depth-dose distributions [71], lateral profiles of vertically scanned line profiles [75] and Spread-Out Bragg Peak (SOBP) plans [72]. Details on the measurement procedures were given in the mentioned references so only a quick overview will be given here.

Pencil beam depth-dose distributions in water were recorded using a PeakFinder water column (PTW, Freiburg) with a diameter of 8.16 cm. In total, 17 Bragg curves with beam energies spanning the entire energy range available at HIT (from 48.5 to 222.6 MeV) have been measured. The measurements took place in a clinical room at HIT. The resolution was 0.05 mm in the region of the BP.

Measurements of lateral profiles of vertically scanned irradiation lines in a water phantom were obtained at three energies (81.5, 158.5 and 222.6 MeV) using an array of 24 motorized pinpoint chambers (PTW, 0.03 cm<sup>3</sup>) arranged in a block of six rows and four columns. The profiles were recorded perpendicularly to the direction of the vertically scanned line. Each scanned line consisted of 101 pencil beams ranging from -50 mm to +50 mm with a 1 mm spacing. The horizontal profiles were recorded starting from about 16 mm in water to 30 mm after the BP. For each energy, profiles at 42 depths were recorded. The distance between consecutive profiles was between 0.5 and 10 mm.

Three SOBP plans centered around 5 cm, 12.5 and 20 cm in water were created using a FLUKA-based treatment planning tool. The planned dose was 1 Gy within the  $3 \times 3 \times 3$  cm target region. Delivery of the plans happened in the experimental room

at HIT with measurements being done with the same block of pinpoint ionization chambers used for acquiring the lateral profiles described earlier. The profiles were recorded starting at a depth of 16 mm to approximately 20 mm after the end of the SOBP. The step size between measurements in regions of high gradient and in regions of high dose was 1 mm.

### **FLUKA Calculations**

Due to the lack of dosimetric data in magnetic fields, the transport in magnetic fields was benchmarked by comparing MonteRay against FLUKA. For this the effect of homogenous magnetic fields, applied perpendicular to the beam's direction, was studied for field strengths of 0.5, 1.0 and 2 T. In FLUKA, magnetic fields were enabled using the MGNFIELD card with default settings. The DEFAULTS card with value PRECISIO was enabled during FLUKA simulations to ensure high precision simulations.

#### Patient Planning

Patient planning was performed in the clinical TPS RayStation 10 A (RaySearch Laboraries, Stockholm, Sweden) on an anonymized DICOM patient data set representative of a meningioma treatment. A proton treatment plan using a single beam at 90° was optimized for evaluation of dose calculation accuracies in a patient anatomy. The initial spot positioning (hexagonal grid with spot spacing of 3.6 mm, energy spacing of 2.1 mm) and minimum number of particles (580.000 particles) settings follow clinical practice at HIT. Optimization was made on the planning target volume (PTV, ~112 cm<sup>3</sup>) for 49.1 Gy/ 54 GyRBE in 30 fractions using a constant radiobiological effectiveness of 1.1. The resultant energy range spanned from ~78 to 151 MeV. The dose grid was set to  $2 \times 2 \times 2 \text{ mm}^3$  in RayStation with a dose uncertainty of 0.5%. The treatment plan was exported in FLUKA and MonteRay for forward calculation with and without a magnetic field. The statistical uncertainty of the MonteRay and FLUKA runs was 1%. The dose uncertainty was estimated using the batch method. Dose cubes stemming



from FLUKA MC and MonteRay were ultimately imported in RayStation for dosimetric analysis (DVH and line profile evaluation). All doses were computed as dose-to-water and dose comparisons were made in Gy.

# RESULTS

# **Pristine Bragg Peaks in Water**

To evaluate the accuracy of MonteRay, we first compare the simulated dose in water  $d_{MR}$  to the dose measured at HIT  $d_{HIT}$  for 17 quasi-monoenergetic beams. The beam energies ranged from 71.5 to 222.6 MeV. Figure 2 shows a comparison of the dose obtained with MonteRay with measured values for three exemplary energies of 71.5, 158.5 and 222.6 MeV. Due to the high resolution of the measured data (up to 0.05 mm in the BP region), the transport was performed on a Cartesian grid with  $0.1 \times 0.1 \times 0.1 \text{ mm}^3$  resolution. Scoring likewise was done in 0.1 mm thick slices. To match the physical dimension of the detector, scoring was performed in a cylindrical volume with a radius of 4.08 cm. Both measurements and simulations were normalized to one at the BP. Across all the energies, the maximum, minimum and mean  $\Delta R_{80}$  values were 0.16, 0.06 and 0.10 mm, respectively. Once the MC calculations were shifted by  $\Delta \mathbf{R}_{80}$ ,  $d_{MC}$  and  $d_{HIT}$  were quantitively compared using the relative error  $\varepsilon_{rel}$ . The dose threshold for calculating  $\varepsilon_{rel}$  was set to 20% of maximum. The mean absolute  $\varepsilon_{rel}$  over all the investigated energies was 0.56 %.

For the verification of the lateral parametrization in water, measurements of vertically scanned proton beam lines, as described in *Dosimetric Data*, were compared against MonteRay simulations. Lateral relative dose profiles at three energies, 81.5, 158.5 and 222.6 MeV, and at 40 different depths were compared. In **Figure 3** and for each energy, lateral profiles at three depths are visualized: at the entrance (top row), in the BP region (bottom row) and in the middle of these two (middle row). The depths are reported in each panel of **Figure 3**. The corresponding energy is given at the top of each column. After correcting for the error in FWHM already present at the entrance due to daily variations in the beam's shape, on

average, the simulated FWHM matched the experimental data's FWHM within 0.1, 0.3 and 0.5 mm for the three energies, respectively. Likewise, the FW10%M values matched to within 0.1, 0.3 and 0.9 mm.

# Spread Out Bragg Peaks in Water

Next, MonteRay's simulated dose was compared with dosimetric data from SOBP plans. The measurement process was described in **Dosimetric Data**. The resulting depth-dose distributions are displayed in **Figure 4**, together with the measured values. The mean absolute relative error between measurements and predictions (excluding data in regions of high dose gradients, as performed in clinical routine) was (0.69%, 0.74%, 1.0%) with a standard deviation of (0.7%, 0.6%, 1.0%). The  $\Delta \mathbf{R}_{80}$  values were 0.5, 0.3 and 0.3 mm, respectively. In the lower panels of **Figure 4**, lateral profiles at the entrance and at in the middle of the SOBP are shown. Here, the simulated SOBP widths matched the experimental ones on to within about 1 mm.

# Magnetic Field Deflection in Homogenous Fields

To judge the accuracy of MonteRay when dealing with homogenous magnetic fields, MonteRay's simulations were first compared to FLUKA's for monoenergetic proton beams incident on water. The magnetic field was applied perpendicular to the beam's direction and four field strengths of 0 T, 0.5 T, 1 T and 2 T were compared. Planar profiles were scored with a resolution of  $1 \times 1 \times 1 \text{ mm}^3$  but were afterwards integrated along 1 cm in the direction of the magnetic field axis to provide higher statistics. In **Figures 5A,B**, 2D dose distributions, perpendicular to the magnetic field, are shown for the case where the magnetic field strength was 2 T. In panel (**A**), MonteRay's results are shown while FLUKA's results are displayed in panel (**B**). For all tested field strengths, the gamma passing rate (as defined in *Comparison Metrics*) was above 99.8%

In **Figure 5C**, lateral profiles at the BP position for the four field strengths are shown. From lateral profiles, COM, FWHM and FW%10M were computed at each depth up to the BP. The maximum differences in COMs ( $\Delta COM$ ), FWHM ( $\Delta FW_{50}$ ) and FW10%M ( $\Delta FW_{10}$ ) between MonteRay and FLUKA are summarized in **Table 1**. For all tested field strengths and at all depths, the maximum distances between the COMs stayed below 0.15 mm, the maximum disagreements in the FWHM reached 0.21 mm while the maximum disagreements in the FW10%M reached 0.31 mm. Comparing integrated depth-dose profiles, the  $R_{80}$  values between MonteRay and FLUKA were found to agree to within 0.14, 0.18, 0.10 and 0.07 mm. The maximum relative errors in dose, after correcting for these shifts, was 1.2%.

#### **Patient Case**

In **Figure 6** panels (**A**) and (**B**), the doses for a patient plan, calculated with FLUKA and MonteRay are shown in the axial plane. The gamma passing rate between MonteRay and FLUKA was computed to be 99.8%. In panel (**C**), longitudinal profiles and in panel (**D**), lateral profiles are shown. The profiles are shown for







simulated doses obtained from RayStation, FLUKA and MonteRay, and their locations are indicated in panel (A) through red horizontal (longitudinal) and vertical (lateral) lines. For RayStation, FLUKA and MonteRay, the lateral profile's FWHMs were 67.6, 68.1, and 68.3 mm. The widths at 10% of the maximum were 85.3, 86.1, and 85.9 mm. The differences in range between MonteRay/FLUKA and RayStation/FLUKA were calculated from the longitudinal profiles and found to be 0.4 and 0.6 mm, respectively. Both in terms of lateral and longitudinal profiles, MonteRay agrees well with FLUKA.

In **Figure 7A**, DVHs calculated for several regions of interest (ROI) are displayed: the CTV, the brain, the brainstem and the right optical nerve. The  $D_2$ ,  $D_{50}$  and  $D_{98}$  values were computed for the CTV and  $D_2$  values were computed for the organs at risk (OAR). To judge the quality of MonteRay, the relative difference in  $D_x$  values between MonteRay and FLUKA is compared to those between RayStation and FLUKA. Overall, the agreement



magnetic field. In (C), Lateral profiles for 200 MeV protons in water and with magnetic field strengths of 0 T, 0.5 T, 1 T, and 2 T are displayed at the location of the BP. MonteRay's results are indicated by a red line while FLUKA's results are displayed as blue dots.

**TABLE 1** Comparison of MonteRay against Fluka for a 200 MeV proton beamincident on water with different homogenous magnetic fields appliedperpendicular to the beam. The maximum differences in the COM ( $\Delta COM$ ), FWHM( $\Delta FW_{50}$ ) and FW10%M ( $\Delta FW_{10}$ ) across all depths up to the BP are reported.

Field strength [T]	∆ <i>COM</i> [mm]	∆ <i>FW</i> 50 [mm]	∆ <i>FW</i> <sub>10</sub> [mm]
0	0.018	0.17	0.24
0.5	0.043	0.21	0.30
1.0	0.072	0.19	0.23
2.0	0.14	0.21	0.31

between MonteRay and FLUKA was of the same magnitude as the agreement between RayStation and FLUKA. For the CTV, good agreement in the  $D_2$  value of 0.25%, the  $D_{50}$  value of 0.38% and the  $D_{98}$  value to within 0.58% was found. For the considered OARs the computed  $D_2$  values matched within 0.50% for the brain, within 0.44% for the brainstem and to within 0.49% for the right optical nerve.

# Patient Case With a Magnetic Field

To benchmark our magnetic field implementation, the previous patient plan was reused but for the dose calculation in MonteRay and FLUKA, a homogenous magnetic field of 1 T was applied throughout the CT volume. In **Figure 8**, the calculated doses in FLUKA (Panel (A)) and MonteRay (Panel (B)) are displayed. With the magnetic field enabled, the gamma passing rate between MonteRay and FLUKA was found to be 98.8%.

In panel (C), longitudinal profiles and in panel (D), lateral profiles are shown, and their locations are indicated in panel (A) through horizonal (longitudinal) and vertical (lateral) lines. Profiles are shown for simulated doses obtained with MonteRay and FLUKA. Additionally, in panel (D), the lateral profile obtain d from RayStation without an applied magnetic field is shown. The deflection observed at the lateral profile's position was ~5 mm. Computed for FLUKA and MonteRay, the lateral profile's FWHMs were 67.4 mm, 67.5 mm. The widths at 10% of the maximum were 86.0 and 85.0 mm. The difference in range between MonteRay and FLUKA, calculated from the longitudinal profiles, was found to be 0.4 mm.

In **Figure 7B**, DVHs calculated on the same ROIs as in the previous section are shown.  $D_x$  values were computed for FLUKA and MonteRay. For the CTV we found agreement in the  $D_2$  value of 2%, in the  $D_{50}$  value of 0.53% and in the  $D_{98}$  value of 1.2%. For the OARs, the computed  $D_2$  values matched within 0.76% for the brain, within 2.1% for the brainstem and within 2.3% for the right optical nerve.

# **Runtime Benchmarks**

The performance of MonteRay was evaluated for various test cases. All tests were performed on a six-core AMD Ryzen 5,3600 processor. The transport grid's resolution was set to  $2 \times 2 \times 2 \text{ mm}^3$ . This resolution is used clinically at HIT and other fast MC codes have used this resolution for benchmarking [31]. For 150 MeV monoenergetic Protons in water with a FWHM of 1 cm, a throughput of 31 k primaries per second on a single core and 180 k primaries per second when using all six cores of the CPU, was measured. Under parallel load, the throughput therefore was 30 k primaries per second per core. In comparison, the computational throughput of FLUKA on the same problem on the same hardware was 1.1 k primaries per second.

For the patient plan, benchmarks were run on a  $2 \times 2 \times 2$  mm<sup>3</sup> grid with 5,000 particles per pencil beam per core. In total, the plan consisted of 8313 pencil beams. On a single core, a throughput of 33 k particles per second was observed while the throughput on six core was measured to be 193 k primaries per second which corresponds to 32 k primaries per seconds per core.

# DISCUSSION

The comparison of MonteRay predictions against dosimetric data and FLUKA simulations confirms that the implemented



FIGURE 6 | Axial views of calculated doses for the plan described in Section 2.2.4 are shown for (A) FLUKA and (B) MonteRay. In panels (C) and (D), longitudinal and lateral profiles are shown, respectively. The locations of the profiles relative to the 2D plots are indicated trough red lines in panel (A). RayStation profiles are indicated by a solid green line, FLUKA profiles by a dotted blue line and MonteRay profiles by a dashed red line.



electromagnetic and nuclear models correctly reproduce the underlying physics. In terms of depth-dose distributions for pencil beams in water (*Pristine Bragg Peaks in Water*), the mean absolute relative error over all 17 compared energies was 0.56%, ranging from 0.33 to 0.60% for 102.6 and 222.6 MeV protons, respectively. The depth-dependent maximum absolute relative error varied from 0.95% (48.5 MeV) to 3.4% (222.6 MeV). The latter is located at the entrance channel of the highest energy (222.6 MeV) which is typically not used for clinical purpose. This underestimation could in part be explained through the fact that the current approach for sampling the initial particles neglects secondary d, t, <sup>3</sup>He and <sup>4</sup>He particles produced in the beamline. Our predictions are in line with other fast MC engines available in literature, for example [73], using FRED have found relative differences of up to about 3% for 200 MeV protons in water.

In terms of lateral evolution as function of depth, MonteRay matched satisfactorily the experimental data in terms of FWHM/FW10%M within on average 0.1, 0.3, and 0.9 mm for low, medium and high energies. The largest difference has been found in the Bragg peak region for 222.6 MeV protons with a maximum variation of the FW10%M of 2 mm. To evaluate possible shortcomings in the scattering model, we have compared FLUKA and MonteRay predictions for 200 MeV proton beams in water without the HIT beamline. The maximum FWHM(FW10%M) variation found was



0.17 mm (0.24 mm) and the 3D gamma pass rate was 99.8% confirming the quality of the implemented model.

Prediction of SOBPs centered at different depths confirmed MonteRay's beam-model with an average agreement of 1% when compared against experimental data, well fulfilling clinical criteria. MonteRay's results have been found to be in line with FLUKA results for the same set of experimental SOBP data [71], with average FLUKA dose deviations of 0.9%.

Evaluation of MonteRay on a patient plan showed good agreement against simulations performed with FLUKA. In terms of D2, D50, and D98 we achieved similar agreement to FLUKA as RayStation did. The 3D gamma pass rate was calculated to be 99.8% showing that the implemented models and approximations for electromagnetic and nuclear interactions approximate the underlying physics well, also in a clinical setting. Computed 3D gamma pass rates were in line with those obtained by other fast MC engines [28, 33, 73].

Similarly, we evaluated the quality of our simulation when an additional magnetic field was applied to an irradiation plan. Compared to FLUKA, we found adequate agreement in terms of D2, D50, and D98 between 0.5 and 2.3%. The 3D gamma pass rate was 98.9%, showing that a simple approximation of the Lorentz force is adequate at describing the transport of charged particles in homogenous magnetic fields.

In terms of computational throughput, MonteRay was able to simulate 31 k primaries per second for a 150 MeV proton beam incident on water, transported on a  $2 \times 2 \times 2 \text{ mm}^3$  grid. Parallel execution on six cores was found to scale linearly, achieving a throughput of 180 k primaries per second. When benchmarked on a patient plan containing ~8300 pencil beams with energies ranging from ~78 to ~150 MeV, we measured a throughput of 33 k particles per seconds on a single core and 193 k particles on six cores. Again, linear scaling was observed which demonstrates that reading the phase space from disk is not a bottleneck, even when multiple cores are competing for random read access.

# **CONCLUSION AND OUTLOOK**

In this work we have presented a novel MC engine, specialized for proton therapy calculations, currently under development at HIT. Good agreement with measured data and a full-fledged MC engine (FLUKA) has been found. MonteRay achieved fast tracking rates of more than 30 k proton primaries per second at 150 MeV on a  $2 \times 2 \times 2 \text{ mm}^3$  grid. In a next step, work will begin on porting our fast CPU engine onto GPUs. Following a heterogenous approach, i.e. using both CPUs and GPUs, we hope to achieve sub-minute runtimes even for large irradiation plans. A custom Monte Carlo engine will also allow us to easily implement custom features such as computing the linear energy transfer or to add imaging capabilities by producing positrons or prompt gammas.

With helium beam treatment commencing at HIT, inclusion of helium beams in MonteRay is underway with inelastic nuclear databases having already been generated.

With the aim of MR guided ion therapy, we are the first fast MC engine to include magnetic field support. In the future we will expand our evaluation to inhomogeneous fields with a focus on simulating MRIs which are being installed at HIT for the purpose of MR guided ion therapy.

# DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

# AUTHOR CONTRIBUTIONS

AM, AF, and PL were responsible for the conceptual design of the Monte Carlo engine. PL, BK, and AM developed the source code of the Monte Carlo engine. AM generated the materials database, including elastic and inelastic nuclear cross sections. AF

# REFERENCES

- Chandarana H, Wang H, Tijssen RHN, and Das IJ Emerging Role of MRI in Radiation Therapy. J Magn Reson Imaging (2018) 48:1468–78. doi:10.1002/ jmri.26271
- Pollard JM, Wen Z, Sadagopan R, Wang J, and Ibbott GS The Future of Image-Guided Radiotherapy Will Be MR Guided. *Bjr* (2017) 90:20160667. doi:10.1259/bjr.20160667
- Mutic S, and Dempsey JF The ViewRay System: Magnetic Resonance-Guided and Controlled Radiotherapy. *Semin Radiat Oncol* (2014) 24:196–9. doi:10.1016/j.semradonc.2014.02.008
- Liney GP, Whelan B, Oborn B, Barton M, and Keall P MRI-linear Accelerator Radiotherapy Systems. *Clin Oncol* (2018) 30:686–91. doi:10.1016/j.clon.2018.08.003
- Acharya S, Fischer-Valuck BW, Kashani R, Parikh P, Yang D, Zhao T, et al. Online Magnetic Resonance Image Guided Adaptive Radiation Therapy: First Clinical Applications. *Int J Radiat Oncology\*Biology\*Physics* (2016) 94: 394–403. doi:10.1016/j.ijrobp.2015.10.015
- Durante M, and Loeffler JS Charged Particles in Radiation Oncology. Nat Rev Clin Oncol (2010) 7:37–43. doi:10.1038/nrclinonc.2009.183
- Durante M, Orecchia R, and Loeffler JS Charged-particle Therapy in Cancer: Clinical Uses and Future Perspectives. *Nat Rev Clin Oncol* (2017) 14:483–95. doi:10.1038/nrclinonc.2017.30
- Hoffmann A, Oborn B, Moteabbed M, Yan S, Bortfeld T, Knopf A, et al. MRguided Proton Therapy: a Review and a Preview. *Radiat Oncol* (2020) 15:129. doi:10.1186/s13014-020-01571-x
- Haberer T, Debus J, Eickhoff H, Jäkel O, Schulz-Ertner D, and Weber U The heidelberg Ion Therapy center. *Radiother Oncol* (2004) 73:S186–S190. doi:10.1016/s0167-8140(04)80046-x
- Rankine LJ, Mein S, Cai B, Curcuru A, Juang T, Miles D, et al. Three-Dimensional Dosimetric Validation of a Magnetic Resonance Guided Intensity Modulated Radiation Therapy System. *Int J Radiat Oncol Biol Phys* (2017) 97:1095–104. doi:10.1016/j.ijrobp.2017.01.223
- Klüter S Technical Design and Concept of a 0.35 T MR-Linac. Clin Translational Radiat Oncol (2019) 18:98–101. doi:10.1016/j.ctro.2019.04.007

developed the code for the generation of inelastic nuclear databases from FLUKA. JB generated the inelastic nuclear databases. PL, TT, and AM worked on the analysis of data. TT, AM, and SM collected and provided experimental data used in this work. TT computed and provided the patient plan and SOBP plans. JD and TH provided clinical direction during project development, manuscript writing and project administration and funding acquisition. All authors read and contributed to the preparation of the manuscript.

# FUNDING

The authors acknowledge financial support through the German Federal Ministry of Education and Research (BMBF) within the project (Grant number: 13GW0436A).

# ACKNOWLEDGMENTS

The authors would like to acknowledge Eric Heim's work on the initial setup of the C++ code base and unit testing framework. The authors would like to acknowledge Ahmad Neishabouri for his help with performing Fluka calculations and Eric Heim for his work on the initial setup of the C++ code base and the unit testing framework.

- Chamberlain M, Krayenbuehl J, van Timmeren JE, Wilke L, Andratschke N, Garcia Schüler H, et al. Head and Neck Radiotherapy on the MR Linac: a Multicenter Planning challenge Amongst MRIdian Platform Users. *Strahlenther Onkol* (2021) 1–11. doi:10.1007/s00066-021-01771-8
- Raaijmakers AJE, Raaymakers BW, and Lagendijk JJW Magnetic-fieldinduced Dose Effects in MR-Guided Radiotherapy Systems: Dependence on the Magnetic Field Strength. *Phys Med Biol* (2008) 53:909–23. doi:10.1088/ 0031-9155/53/4/006
- Wolf R, and Bortfeld T An Analytical Solution to Proton Bragg Peak Deflection in a Magnetic Field. *Phys Med Biol* (2012) 57:N329–N337. doi:10.1088/0031-9155/57/17/N329
- Moteabbed M, Schuemann J, and Paganetti H Dosimetric Feasibility of Real-Time MRI-Guided Proton Therapy. *Med Phys* (2014) 41:111713. doi:10.1118/ 1.4897570
- Ferrari A, Sala PR, Fasso A, and Ranft J FLUKA: A Multi-Particle Transport Code. Stanford: Stanford linear accelerator center (2005). doi:10.2172/877507
- Böhlen TT, Cerutti F, Chin MPW, Fassò A, Ferrari A, Ortega PG, et al. The FLUKA Code: Developments and Challenges for High Energy and Medical Applications. *Nucl Data Sheets* (2014) 120:211–4. doi:10.1016/j.nds.2014.07.049
- Bauer J, Sommerer F, Mairani A, Unholtz D, Farook R, Handrack J, et al. Integration and Evaluation of Automated Monte Carlo Simulations in the Clinical Practice of Scanned Proton and Carbon Ion Beam Therapy. *Phys Med Biol* (2014) 59:4635–59. doi:10.1088/0031-9155/59/16/4635
- Mein S, Choi K, Kopp B, Tessonnier T, Bauer J, Ferrari A, et al. Fast Robust Dose Calculation on GPU for High-Precision 1H, 4He, 12C and 16O Ion Therapy: the FRoG Platform. *Sci Rep* (2018) 8:14829. doi:10.1038/s41598-018-33194-4
- Mein S, Kopp B, Tessonnier T, Ackermann B, Ecker S, Bauer J, et al. Dosimetric Validation of Monte Carlo and Analytical Dose Engines with Raster-Scanning 1H, 4He, 12C, and 16O Ion-Beams Using an Anthropomorphic Phantom. *Physica Med* (2019) 64:123–31. doi:10.1016/ j.ejmp.2019.07.001
- Choi K, Mein S, Kopp B, Magro G, Molinelli S, Ciocca M, et al. FRoG-A New Calculation Engine for Clinical Investigations with Proton and Carbon Ion Beams at CNAO. *Cancers* (2018) 10:395. doi:10.3390/cancers10110395

- Kopp B, Fuglsang Jensen M, Mein S, Hoffmann L, Nyström H, Falk M, et al. FRoG: An Independent Dose and LET D Prediction Tool for Proton Therapy at ProBeam Facilities. *Med Phys* (2020) 47:5274–86. doi:10.1002/ mp.14417
- Magro G, Mein S, Kopp B, Mastella E, Pella A, Ciocca M, et al. FRoG Dose Computation Meets Monte Carlo Accuracy for Proton Therapy Dose Calculation in Lung. *Physica Med* (2021) 86:66–74. doi:10.1016/ j.ejmp.2021.05.021
- Fuchs H, Moser P, Gröschl M, and Georg D Magnetic Field Effects on Particle Beams and Their Implications for Dose Calculation in MR-Guided Particle Therapy. *Med Phys* (2017) 44:1149–56. doi:10.1002/mp.12105
- Parodi K Vision 20/20: Positron Emission Tomography in Radiation Therapy Planning, Delivery, and Monitoring. *Med Phys* (2015) 42:7153–68. doi:10.1118/1.4935869
- 26. Parodi K, Paganetti H, Shih HA, Michaud S, Loeffler JS, DeLaney TF, et al. Patient Study of *In Vivo* Verification of Beam Delivery and Range, Using Positron Emission Tomography and Computed Tomography Imaging after Proton Therapy. *Int J Radiat Oncol Biol Phys* (2007) 68:920–34. doi:10.1016/ j.ijrobp.2007.01.063
- Parodi K, and Polf JC In Vivo range Verification in Particle Therapy. Med Phys (2018) 45:e1036–e1050. doi:10.1002/mp.12960
- Jia X, Schümann J, Paganetti H, and Jiang SB GPU-based Fast Monte Carlo Dose Calculation for Proton Therapy. *Phys Med Biol* (2012) 57:7783–97. doi:10.1088/0031-9155/57/23/7783
- Jia X, Pawlicki T, Murphy KT, and Mundt AJ Proton Therapy Dose Calculations on GPU: Advances and Challenges. *Translational Cancer Res* (2012) 1:207–16. doi:10.3978/j.issn.2218-676X.2012.10.03
- Giantsoudi D, Schuemann J, Jia X, Dowdell S, Jiang S, and Paganetti H Validation of a GPU-Based Monte Carlo Code (gPMC) for Proton Radiation Therapy: Clinical Cases Study. *Phys Med Biol* (2015) 60:2257–69. doi:10.1088/ 0031-9155/60/6/2257
- 31. Schiavi A, Senzacqua M, Pioli S, Mairani A, Magro G, Molinelli S, et al. Fred: a GPU-Accelerated Fast-Monte Carlo Code for Rapid Treatment Plan Recalculation in Ion Beam Therapy. *Phys Med Biol* (2017) 62:7482–504. doi:10.1088/1361-6560/aa8134
- 32. Deng W, Younkin JE, Souris K, Huang S, Augustine K, Fatyga M, et al. Technical Note: Integrating an Open Source Monte Carlo Code "MCsquare" for Clinical Use in Intensity-modulated Proton Therapy. *Med Phys* (2020) 47: 2558–74. doi:10.1002/mp.14125
- Tian Z, Shi F, Folkerts M, Qin N, Jiang SB, and Jia X A GPU Opencl Based Cross-Platform Monte Carlo Dose Calculation Engine (Gomc). *Phys Med Biol* (2015) 60:7419–35. doi:10.1088/0031-9155/60/19/7419
- 34. Faddegon B, Ramos-Méndez J, Schuemann J, McNamara A, Shin J, Perl J, et al. The TOPAS Tool for Particle Simulation, a Monte Carlo Simulation Tool for Physics, Biology and Clinical Research. *Physica Med* (2020) 72:114–21. doi:10.1016/j.ejmp.2020.03.019
- Oborn BM, Dowdell S, Metcalfe PE, Crozier S, Mohan R, and Keall PJ Proton Beam Deflection in MRI fields: Implications for MRI-Guided Proton Therapy. *Med Phys* (2015) 42:2113–24. doi:10.1118/1.4916661
- Padilla-Cabal F, Georg D, and Fuchs H A Pencil Beam Algorithm for Magnetic Resonance Image-Guided Proton Therapy. *Med Phys* (2018) 45:2195–204. doi:10.1002/mp.12854
- Schellhammer SM, Hoffmann AL, Gantz S, Smeets J, van der Kraaij E, Quets S, et al. Integrating a Low-Field Open MR Scanner with a Static Proton Research Beam Line: Proof of Concept. *Phys Med Biol* (2018) 63:23LT01. doi:10.1088/ 1361-6560/aaece8
- Schellhammer SM, and Hoffmann AL Prediction and Compensation of Magnetic Beam Deflection in MR-Integrated Proton Therapy: a Method Optimized Regarding Accuracy, Versatility and Speed. *Phys Med Biol* (2017) 62:1548–64. doi:10.1088/1361-6560/62/4/1548
- GitHub, Google/Googletest (2021) Available from: https://github.com/google/ googletest. (Accessed July 08, 2021).
- GitHub, Google/Benchmark (2021) Available from: https://github.com/google/ benchmark (Accessed July 08, 2021).
- Boost C++ Libraries (2021) Available from: https://www.boost.org/ (Accessed July 09, 2021).
- RapidXml (2009) Available from: http://rapidxml.sourceforge.net/ (Accessed July 08, 2021).

- McCormick M, Liu X, Jomier J, Marion C, and Ibanez L ITK: Enabling Reproducible Research and Open Science. Front Neuroinform (2014) 8:13. doi:10.3389/fninf.2014.00013
- 44. Wilkens T dicom.offis.de Home (2018). [cited 2021 Jul 10]. Available from: https://dcmtk.org/.
- Schneider U, Pedroni E, and Lomax A The Calibration of CT Hounsfield Units for Radiotherapy Treatment Planning. *Phys Med Biol* (1996) 41:111–24. doi:10.1088/0031-9155/41/1/009
- 46. Parodi K, Ferrari A, Sommerer F, and Paganetti H Clinical CT-based Calculations of Dose and Positron Emitter Distributions in Proton Therapy Using the FLUKA Monte Carlo Code. *Phys Med Biol* (2007) 52:3369–87. doi:10.1088/0031-9155/52/12/004
- 47. Qin N, Pinto M, Tian Z, Dedes G, Pompos A, Jiang SB, et al. Initial Development of goCMC: a GPU-Oriented Fast Cross-Platform Monte Carlo Engine for Carbon Ion Therapy. *Phys Med Biol* (2017) 62:3682–99. doi:10.1088/1361-6560/aa5d43
- Parodi K, Mairani A, and Sommerer F Monte Carlo-Based Parametrization of the Lateral Dose Spread for Clinical Treatment Planning of Scanned Proton and Carbon Ion Beams. J Radiat Res (2013) 54(1):i91–i96. doi:10.1093/jrr/ rrt051
- Tessonnier T, Marcelos T, Mairani A, Brons S, and Parodi K Phase Space Generation for Proton and Carbon Ion Beams for External Users' Applications at the Heidelberg Ion Therapy Center. *Front Oncol* (2015) 5:297. doi:10.3389/ fonc.2015.00297
- Seltzer SM An Overview of ETRAN Monte Carlo Methods. In: Monte Carlo Transport of Electrons and Photons. Boston, MA: Springer (1988). p. 153–81. doi:10.1007/978-1-4613-1059-4\_7
- Alex F Bielajew. "Electron Transport in E and B Fields. In: Monte Carlo Transport of Electrons and Photons. Boston, MA: Springer (1988). p. 421-34.
- 52. Duff T, Burgess J, Christensen P, Hery C, Kensler A, Liani M, et al. Building an Orthonormal Basis, Revisited. *J Comp Graphics Tech* (2017) 6:1-8.
- 53. Jackson JD Classical Electrodynamics. New York, NY: Wiley (1975).
- Fano U Penetration of Protons, Alpha Particles, and Mesons. Annu Rev Nucl Sci (1963) 13:1–66. doi:10.1146/annurev.ns.13.120163.000245
- Landau LD On the Energy Loss of Fast Particles by Ionization. J Phys (1944) 8: 201–5.
- Vavilov PV Ionization Losses of High-Energy Heavy Particles. Soviet Phys JETP (1957) 5:749–51.
- Chibani O New Algorithms for the Vavilov Distribution Calculation and the Corresponding Energy Loss Sampling. *IEEE Trans Nucl Sci* (1998) 45:2288–92. doi:10.1109/23.725266
- Moliere G Theorie der Streuung schneller geladener Teilchen II Mehrfach-und Vielfachstreuung. Z f
  ür Naturforschung A (1948) 3:78–97. doi:10.1515/zna-1948-0203
- Scott WT The Theory of Small-Angle Multiple Scattering of Fast Charged Particles. *Rev Mod Phys* (1963) 35:231–313. doi:10.1103/RevModPhys.35.231
- Rossi B, and Greisen K Cosmic-Ray Theory. *Rev Mod Phys* (1941) 13:240–309. doi:10.1103/RevModPhys.13.240
- Highland VL Some Practical Remarks on Multiple Scattering. Nucl Instr Methods (1975) 129:497–9. doi:10.1016/0029-554x(75)90743-0
- Frühwirth R, and Regler M On the Quantitative Modelling of Core and Tails of Multiple Scattering by Gaussian Mixtures. Nucl Instr Methods Phys Res Section A: Acc Spectrometers, Detectors Associated Equipment (2001) 456:369–89. doi:10.1016/s0168-9002(00)00589-1
- Bellinzona VE, Ciocca M, Embriaco A, Fontana A, Mairani A, Mori M, et al. On the Parametrization of Lateral Dose Profiles in Proton Radiation Therapy. *Physica Med* (2015) 31:484–92. doi:10.1016/j.ejmp.2015.05.004
- Kuhn SE, and Dodge GE A Fast Algorithm for Monte Carlo Simulations of Multiple Coulomb Scattering. Nucl Instr Methods Phys Res Section A: Acc Spectrometers, Detectors Associated Equipment (1992) 322:88–92. doi:10.1016/ 0168-9002(92)90361-7
- Adelmann A, Calvo P, Frey M, Gsell A, Locans U, Metzger-Kraus C, et al. OPAL a Versatile Tool for Charged Particle Accelerator Simulations. arxiv: 1905.06654 (2019).
- Bellinzona VE A Non Gaussian Model for the Lateral Dose Evaluation in Hadrontherapy. [PhD thesis]. Ludwig-Maximillians-University Munich (2017).

- Tripathi RK, Wilson JW, and Cucinotta FA A Method for Calculating Proton-Nucleus Elastic Cross-Sections. Nucl Instr Methods Phys Res Section B: Beam Interactions Mater Atoms (2002) 194:229–36. doi:10.1016/s0168-583x(02) 00690-0
- Ranft J Estimation of Radiation Problems Around High-Energy Accelerators Using Calculations of the Hadronic cascade in Matter. *Part Accel* (1972) 3: 129–61.
- Tripathi RK, Cucinotta FA, and Wilson JW Accurate Universal Parameterization of Absorption Cross Sections. Nucl Instr Methods Phys Res Section B: Beam Interactions Mater Atoms (1996) 117:347–9. doi:10.1016/0168-583X(96)00331-X
- Tripathi RK, Cucinotta FA, and Wilson JW Accurate Universal Parameterization of Absorption Cross Sections III - Light Systems. Nucl Instr Methods Phys Res Section B: Beam Interactions Mater Atoms (1999) 155:349–56. doi:10.1016/s0168-583x(99)00479-6
- Tessonnier T, Mairani A, Brons S, Haberer T, Debus J, and Parodi K Experimental Dosimetric Comparison of1H,4He,12C and16O Scanned Ion Beams. *Phys Med Biol* (2017) 62:3958–82. doi:10.1088/1361-6560/aa6516
- 72. Tessonnier T, Böhlen TT, Ceruti F, Ferrari A, Sala P, Brons S, et al. Dosimetric Verification in Water of a Monte Carlo Treatment Planning Tool for Proton, Helium, Carbon and Oxygen Ion Beams at the Heidelberg Ion Beam Therapy Center. *Phys Med Biol* (2017) 62:6579–94. doi:10.1088/ 1361-6560/aa7be4
- Gajewski J, Garbacz M, Chang C-W, Czerska K, Durante M, Krah N, et al. Commissioning of GPU-Accelerated Monte Carlo Code FRED for Clinical Applications in Proton Therapy. *Front Phys* (2021) 8:403. doi:10.3389/ fphy.2020.567300

- 74. Garbacz M, Battistoni G, Durante M, Gajewski J, Krah N, Patera V, et al. Proton Therapy Treatment Plan Verification in CCB Krakow Using Fred Monte Carlo TPS Tool. In: World Congress on Medical Physics and Biomedical Engineering 2018. Singapore: Springer (2019). p. 783–7. doi:10.1007/978-981-10-9035-6\_144
- 75. Tessonnier T Treatment of Low-Grade Meningiomas with Protons and Helium Ions. [PhD thesis]. Ludwig-Maximillians-University Munich (2017).

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Lysakovski, Ferrari, Tessonnier, Besuglow, Kopp, Mein, Haberer, Debus and Mairani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.